Zoledronic acid (Reclast) Injectable Osteoporosis Drug Information by MedicineNet.com
Zoledronic acid very is the active narcotic in Zometa. Bone is in a fixed homeland of remodeling in which getting on bone is removed by cells called osteoclasts, and virgin bone is laid down by cells called osteoblasts. Zoledronic acid inhibits bone emigration by osteoclasts. The FDA approved Reclast in Aug 2007.
DOSING: Zoledronic acid is habituated intravenously over no less than 15 minutes. Paget's disease of bone is treated with a unmarried 5 mg infusion. Patients with Paget's disease should besides cop 1500 mg of elemental calcium and 800 IU vitamin D daily, exclusively during the 2 weeks after the injection of zoledronic acid. DRUG INTERACTIONS: Combining zoledronic acid with aminoglycosides or loop diuretics may sway to reduced calcium in blood.
Zoledronic acid should be used with caution in patients who are fascinating drugs that modify kidney function. Women of childbearing interval should be advised to appliance a trustworthy disposition of birth control. NURSING MOTHERS: It is not confessed if zoledronic acid is excreted in human milk. Severe bone, joint, and muscle grief may occur.
